List view / Grid view
A review has been published by experts in neurodegeneration research, detailing six ways to improve dementia research. This article investigates one of these suggestions, focusing on how we can improve drug target identification.
An international research team has identified three new genes linked to the risk of Alzheimer’s disease...
31 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The UK's Medical Research Council (MRC) has created an interactive "map" that identifies biomedical research funding opportunities for researchers...
21 October 2015 | By Kate Douetil
This innovative new global investment fund has gained support from a wide variety of investors, including the UK Government’s Department of Health (DoH), Alzheimer’s Research UK and world-leading major pharmaceutical companies Biogen, GlaxoSmithKline, Johnson & Johnson, Lilly, Pfizer and Takeda...
12 October 2015 | By Victoria White
The Dementia Consortium is a £3.5m drug discovery collaboration between Alzheimer’s Research UK, MRC Technology, Eisai, Lilly and now Astex...
16 September 2015 | By Victoria White
A team at the International Centre for Genetic Engineering and Biotechnology (ICGEB) will join forces with MRC Technology to take on the project...
22 June 2015 | By Victoria White
The Dementia Consortium is funding a new project to target the immune system in the hunt for new treatments for Alzheimer's disease...
Dementia is a global crisis with 76 million people worldwide expected to be living with the condition by 2030. Current symptomatic treatments provide modest improvements in cognition but disease-modifying therapies for diseases like Alzheimer’s – the most common cause of dementia – do not yet exist.
18 February 2015 | By Alzheimer’s Research UK
Institutes at Universities of Cambridge, Oxford and UCL will form £30m Drug Discovery Alliance...
